NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Crispr Therapeutics AG CRSP
12 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 3.5M
Revenue, FY2025 · full 12-year series below
Revenue $M
Net income $M
FY2025 · Revenue 3.5 · Net income -581.6
Compound annual growth
Revenue compounded at +37.3% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−16570 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -18933.6% · Net -16569.8%
ROE
FY2025 · ROE -30.2%
Each USD of equity lost 30 cents this year.
The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.4 | 0.0 | 0.9 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.7 | −0.5 | −0.2 | −0.7 | 0.4 | −0.4 | 0.0 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.6 | −0.4 | −0.2 | −0.6 | 0.4 | −0.3 | 0.1 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Net income $B | −0.6 | −0.4 | −0.2 | −0.7 | 0.4 | −0.3 | 0.1 | −0.2 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.3 | −0.1 | −0.3 | −0.5 | 0.5 | −0.3 | 0.0 | −0.1 | −0.1 | −0.1 | 0.1 | · |
| EPS, diluted $ | −6.47 | −4.34 | −1.94 | −8.36 | 4.70 | −5.29 | 1.17 | −3.44 | −1.71 | −1.89 | −5.06 | 1.97 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −30.2 | −19.2 | −8.2 | −30.4 | 18.6 | −26.8 | 10.0 | −56.9 | −32.5 | −22.8 | · | · |
| Shares out B | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.07 | 0.06 | 0.05 | 0.04 | 0.04 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 46 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 30 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code V8
Fiscal year endsDecember 31
Data on record since2014